欧罗拉专利离子通道阅读器 ICR

离子通道药物的细胞模型高通量筛选

HTS for Ion channel drug research

制药行业的关注焦点，从药物原料问题向药物研发早期中对药物安全性评估的转变，催生了药物研发早期对于离子通道筛选的需要，而且这种需要越来越受到制药行业的关注。例如，药物引起的QT间期延长以及心率失常，已经促使相关药物安全性评估法例的出台，例如S7B、E14指导文件。药物研发早期对于类似潜在风险的评估，将有助于药物研发企业集中精力在已通过毒性评估可以上市的药物上，避免将时间资源投放在不能通过测试的药品，降低企业研发成本。新的离子通道筛选技术以及资源有望彻底改变市场，有望降低药物研发的瓶颈，增大开发力度。随着药物专利的开放，以及药厂努力寻找新的治疗方案，自动化的解决方案更能为此类需要的企业降低费用，提高药物研发以及安全性评估效率。

利用我们优势的仪器，创造性地利用活体细胞进行高通量分析（cold flux assays）

应用

ICR 8000和ICR 12000可应用在以下的离子通道研究：

Aurora公司的离子通道阅读器技术不仅可应用于在细胞水平表达的离子通道靶点，也可应用在合成小泡中表达的离子转运通道或者孔形成蛋白。

如何给欧罗拉留言？

欢迎点击【一键咨询】，【发送留言】后我们会马上联系您，为您的实验或应用需求推荐合适的仪器配置

Assay Services

Aurora Biomed provides functional assay services on an exclusive, out-sourced basis.  
We are currently carrying out assay services for various ion channel targets including hERG safety screen. Several options for these services exist, we can read/test flux assay samples from your experiments on ICR, we can screen your compounds/library in our laboratories or we can accept cell lines to develop assay for you as part of our services.

Aurora Biomed has a team of highly trained molecular biologists have a solid understanding of ion channels and flux assays. We enjoy a challenge and feel confident in providing solutions to further your ion channel screening needs.

We are pleased to offer both cold flux assays using our proprietary Ion Channel Reader technology and manual voltage-clamp electrophysiology assays. 

Cold flux assays utilize tracer ions to study the ion channel of interest.  The method of detection for Aurora Biomed’s cold flux assays is flame atomic absorption spectroscopy as employed by our proprietary Ion Channel Reader technology.  The Ion Channel Reader Series provides a high throughput format for ion channel screening by the flux assay approach.  The use of high throughput assays helps reduce the burden on electrophysiology by providing some idea of which compounds should be screened if resources are limited and not all compounds can be screened with manual-patch clamp.  The cold flux assay approach is ideal for determining which compounds to follow up with electrophysiology as there is a strong linear correlation (R=0.88) and consistently identical drug rank orders between the two methods.

Manual voltage-clamp electrophysiology is the gold-standard for ion channel screening.  Moreover, the FDA requires in vitro electrophysiology studies in conjunction with in vivo studies for compounds submitted for NDA status.  Oocyte-based studies assess potential cellular mechanisms that may not be evident from in vivo data.

The ICR 12000 designed for ultra high throughput screening of compound libraries against ion channel targets. Based on the robustness of Aurora Biomed's ICR technology, the reader offers high sensitivity generating accurate drug rank order matching electrophysiology data. This new member of the ICR series provides the throughput to access compound QT liability early in the drug discovery process.

给我们留言或致电，我们会为您推荐介绍